openPR Logo
Press release

CD47 Targeting Therapeutics Market Analysis Highlighting Rapid Expansion Driven by Cancer Treatment Innovations

07-21-2025 09:57 AM CET | Health & Medicine

Press release from: Insightace Analytic Pvt Ltd.

CD47 Targeting Therapeutics Market

CD47 Targeting Therapeutics Market

CD47 Targeting Therapeutics Market is expected to grow at a 35% CAGR during the forecast period for 2025-2034.

A transmembrane protein called CD47 helps cancer cells survive in various cancer types by glycosylating on the surface of numerous cancer cells. When CD47 binds to the signal-regulatory protein SIRP, it starts an inhibitory signalling pathway in many cancer types that stops malignant cells from being phagocytosed by macrophages. Therefore, blocking the CD47-SIRP signalling pathway can promote macrophage phagocytosis of tumour cells.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1290

The global CD47-targeting therapeutics market growth is driven by several factors, including the increasing utilization of CD47-targeted anti-cancer treatments, an aging population, the high prevalence of various cancer types, and growing public awareness of the benefits associated with these therapies.

Over the forecast period, escalating research and development investments aimed at better understanding CD47-dependent signaling are expected to create new opportunities within the market. Enhanced knowledge in this field may facilitate the development of innovative anti-cancer therapies that inhibit CD47 signaling in malignant cells. However, market expansion may be hindered by challenges such as the high production costs and manufacturing complexities of targeted therapies, potential off-target effects damaging healthy cells, and stringent regulatory requirements for therapeutic approvals.

Regionally, North America is projected to be a significant contributor to the CD47-targeting therapeutics market throughout the forecast period, driven by rising cancer incidence and mortality rates, along with the rapid adoption of novel drugs and treatment modalities. The United States, in particular, plays a pivotal role by supporting extensive research and development initiatives focused on CD47-targeted therapies. Concurrently, the Asia Pacific market is anticipated to experience substantial growth, fueled by increasing use of CD47-targeting anti-cancer therapies, a growing elderly population, the high burden of diverse cancer types, and heightened awareness of the therapeutic advantages offered by CD47 inhibition in the region.

Major market players operating in the CD47 Targeting Therapeutics market include
Conjupro biotherapeutics (US), EpicentRx (US), Forty Seven (US), ImmuneOncia Therapeutics (Korea), ImmuneOnco Biopharmaceuticals (China), Innovent Biologics (China), KAHR Medical (Israel), TG Therapeutics, Adagene, Alector, Inc., Apmonia Therapeutics, I-MAB Biopharma Co., Ltd., Light Chain Bioscience (Switzerland), Morphiex (US), Trillium Therapeutics (Canada), QLSF Biotherapeutics Inc., Phanes Therapeutics, Inc., Bio-Thera Solutions, others.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Recent collaborations and agreements in the market:
• In January 2022, the next-generation CD47 blocker evorpacept, manufactured by ALX Oncology, was accorded orphan drug designation ("ODD") for treating patients with gastroesophageal junction and gastric cancer.
• In September 2021, for US$2.3 billion, Pfizer Inc. (US) purchased Trillium Therapeutics Inc. (Canada), which had CD47 prospects. Pfizer now has a stronger cancer and hematology portfolio thanks to this acquisition.
• In June 2021, to test the efficacy of combining ALX148, a next-generation CD47 blocker, and CYRAMZA (ramucirumab), Lilly's anti-VEGFR2 antibody, for the treatment of gastric cancer, ALX Oncology (US) and Eli Lilly and Company (US) agreed into a clinical study partnership and supply agreement.

Market Segments
Global CD47 Targeting Therapeutics Market, by Target Disease Indication, 2022-2030 (Value US$ Mn)
• Acute Myeloid Leukemia
• Non-Hodgkin Lymphoma
• Colorectal Cancer
• Diffuse Large B-cell Lymphoma
• Myelodysplastic Syndromes
• Non-Small Cell Lung Cancers
• Ovarian Epithelial Cancer
• Oral mucositis
• Small Cell Lung Cancers
• Other Diseases Indications

Unlock Your GTM Strategy:https://www.insightaceanalytic.com/customisation/1290

Global CD47 Targeting Therapeutics Market, by Type of Molecule, 2022-2030 (Value US$ Mn)
• Biologics
• Small Molecule
Global CD47 Targeting Therapeutics Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
o Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global CD47 Targeting Therapeutics market
 To receive an industry overview and future trends in the CD47 Targeting Therapeutics market
 To analyze the CD47 Targeting Therapeutics market drivers and challenges
 To get information on the CD47 Targeting Therapeutics market value (US$Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the CD47 Targeting Therapeutics market industry

Read Overview Report- https://www.insightaceanalytic.com/report/global-cd47-targeting-therapeutics-market-/1290

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CD47 Targeting Therapeutics Market Analysis Highlighting Rapid Expansion Driven by Cancer Treatment Innovations here

News-ID: 4111529 • Views:

More Releases from Insightace Analytic Pvt Ltd.

Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market to Grow at 5.3% CAGR Amid Rising Awareness of PCOS and PMS
Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market to Grow at 5 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market- (By Product Type (Combined Nutritional Supplements, Single Nutritional Supplements), By Type Indication (Perimenopause, PMS), By Formulation (Capsules/Tablets, Powder, Softgels, Other), By Sales Channel (Pharmacies/Drug Stores, Online Sales Channel, Direct Sales Channel, Others)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research
Cell and Gene Therapy CRO Market Forecast Shows Robust Growth Across North America, Europe, and Asia-Pacific
Cell and Gene Therapy CRO Market Forecast Shows Robust Growth Across North Ameri …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cell and Gene Therapy CRO Market- (By Type of Cell Therapy (CAR-NK, CAR-T, TCR-T, and Others), By Type of Genetic Modification (Ex vivo and In vivo), By Stage of Development (Discovery, Preclinical, and Clinical)), By Therapeutic Area, By End-user, By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by
Bioseparation Systems Market Top Companies Study - GE Healthcare Life Sciences, Pall Corporation, 3M Company, Waters Corporation.
Bioseparation Systems Market Top Companies Study - GE Healthcare Life Sciences, …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Bioseparation Systems Market- (By Type (Centrifugation Technology, Cell Disruption Technology, Chromatography Technique, Extraction Technique, Filtration Technologies and Membrane-based Bioseparation and Precipitation), Application (Food, Life Sciences, Pharmaceutical and Biopharmaceutical)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Bioseparation Systems Market is valued at US$
Medical Nutrition Market Key Players Analysis - Abbott Laboratories; Pfizer Inc.; Bayer AG; Nestle S.A.; GlaxoSmithKline plc.
Medical Nutrition Market Key Players Analysis - Abbott Laboratories; Pfizer Inc. …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Global Medical Nutrition Market Size, Share & Trends Analysis Report By Nutrition Type (Proteins, Carbohydrates, Multivitamins & Antioxidants, Amino Acids, Fibers, Minerals), By Indication (Diabetes, Cancer, Gastrointestinal Diseases, Metabolic Syndromes), By Patient Type (Infants, Adults, And Geriatric Populations), Indication (Diabetes, Cancer, Gastrointestinal Diseases, Metabolic Syndromes), End-User (Home Care Settings, Long-Term Care Facilities, And Ambulatory Surgical

All 5 Releases


More Releases for CD47

CD47 Targeting Therapeutics Market Robust Expansion is expected to 2034
CD47 Targeting Therapeutics Market Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "CD47 Targeting Therapeutics Market By Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers, Other Diseases Indications), By
CD47 Targeting Therapeutics Market Investments, Share and Revenue Analysis Repor …
CD47 Targeting Therapeutics Market Future Pipeline/Clinical Trial Analysis and Revenue Forecast Snapshot - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "CD47 Targeting Therapeutics Market By Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers, Other Diseases Indications), By
CD47 Targeting Therapeutics Market Future Trends and Scope Analysis Report
Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global CD47 Targeting Therapeutics Market- by Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers and Other Diseases Indications), Type of Molecule (Biologics and Small Molecule), Trends, Industry Competition Analysis, Revenue and Forecast To 2030." According to
Future Directions in CD47 Research: Innovations and Clinical Translation
CD47, a protein that plays a critical role in immune evasion by tumor cells, has emerged as a key target in cancer research. Its ability to interact with signal regulatory protein alpha (SIRPα) on macrophages, delivering a "don't eat me" signal that prevents the phagocytosis of tumor cells, has made it a focal point for therapeutic development. As research into CD47 progresses, several innovative approaches and clinical translation efforts are
CD47 Targeting Therapeutics on Target A Multi-Billion Dollar Market Revolutioniz …
CD47 Targeting Therapeutics Market to Record an Exponential CAGR by 2030 - Exclusive Report by InsightAce Analytic Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global CD47 Targeting Therapeutics Market- by Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers and Other Diseases Indications), Type
CD47 Targeting Therapeutics Market Future Trends and Scope Analysis Report
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global CD47 Targeting Therapeutics Market By Target Disease Indication (Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Colorectal Cancer, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral mucositis, Small Cell Lung Cancers, Other Diseases Indications), By Type of molecule(Biologics, Small molecule) - Market Outlook and Industry Analysis 2030" According to the latest research